DCM
KDNY

Dupont Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Dupont Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,922
Closed -$206K – 1436
2020
Q3 		$206K Buy
16,922
+7,210
+74% +$96.6K ﹤0.01% 1110
2020
Q2 		$112K Sell
9,712
-9,232
-49% -$127K ﹤0.01% 1252
2020
Q1 		$260K Buy
+18,944
New +$224K 0.01% 924
2016
Q1 		– Sell
-2,282
Closed -$321K – 713
2015
Q4 		$321K Buy
+2,282
New +$310K 0.01% 614

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dupont Capital Management's KDNY Position: Q4 2020 in Review

Dupont Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2020, closing a stake of 16,922 shares — an estimated $206K sold.

Dupont Capital Management first reported a position in KDNY in Q4 2015 and held it in 4 quarters. The position peaked at $321K in Q4 2015. 77 funds tracked by Wall St. Rank hold KDNY as of Q4 2020.

  • Dupont Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Dupont Capital Management sold 16,922 Chinook Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $206K.
  • Dupont Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
  • Dupont Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $321K in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Dupont Capital Management's 13F filing for Q4 2020, filed 28 Jan 2021.